תבנית:תרופה/דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון - Docetaxel teva 20 mg/vial and 80 mg/vial: הבדלים בין גרסאות
מתוך ויקיתרופות
מ (יצירת תבנית תרופה) |
מ (יצירת תבנית תרופה) |
||
| שורה 10: | שורה 10: | ||
|סל הבריאות={{{סל הבריאות|[[#נתוני סל|כלול בסל]]}}} | |סל הבריאות={{{סל הבריאות|[[#נתוני סל|כלול בסל]]}}} | ||
|במרשם={{{במרשם|כן}}} | |במרשם={{{במרשם|כן}}} | ||
| − | |התוויה={{{התוויה|<div style="direction:ltr;">Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. | + | |התוויה={{{התוויה|<div style="direction:ltr;">Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.</div>}}} |
| − | |התאמת מינון={{{התאמת מינון| | + | |התאמת מינון={{{התאמת מינון|}}} |
| − | |התוויות נגד={{{התוויות נגד| | + | |התוויות נגד={{{התוויות נגד|}}} |
| − | |פרמקודינמיקה={{{פרמקודינמיקה| | + | |פרמקודינמיקה={{{פרמקודינמיקה|}}} |
| − | |פרמקוקינטיקה={{{פרמקוקינטיקה| | + | |פרמקוקינטיקה={{{פרמקוקינטיקה|}}} |
| − | |שימוש בהריון והנקה={{{שימוש בהריון והנקה| | + | |שימוש בהריון והנקה={{{שימוש בהריון והנקה|}}} |
| − | |תגובות בין תרופתיות={{{תגובות בין תרופתיות| | + | |תגובות בין תרופתיות={{{תגובות בין תרופתיות|}}} |
| − | |תופעות לוואי={{{תופעות לוואי| | + | |תופעות לוואי={{{תופעות לוואי|}}} |
|שם יצרן={{{שם יצרן|[[יצרן::PHARMACHEMIE B.V., THE NETHERLANDS]]}}} | |שם יצרן={{{שם יצרן|[[יצרן::PHARMACHEMIE B.V., THE NETHERLANDS]]}}} | ||
|שם יצרן מקוצר=[[שם יצרן מקוצר::PHARMACHEMIE| ]] | |שם יצרן מקוצר=[[שם יצרן מקוצר::PHARMACHEMIE| ]] | ||
| שורה 24: | שורה 24: | ||
|תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::01/2011]]}}} | |תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::01/2011]]}}} | ||
|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Docetaxel teva 20 mg/vial and 80 mg/vial|דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון}}}}} | |קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Docetaxel teva 20 mg/vial and 80 mg/vial|דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון}}}}} | ||
| − | |עלון לרופא={{{עלון לרופא|[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/ | + | |עלון לרופא={{{עלון לרופא|*[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/docetaxel_teva_33399_spc_May_2014_1399968571637.doc עלון לרופא] |
| + | *[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/Worsenings_DocetaxelTeva_SPC_07_01_13_1357566599451.doc עלון לרופא] | ||
| + | *[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/DOCETAXEL_TEVA-dr_1433321005506.pdf עלון לרופא] | ||
| + | *[http://www.old.health.gov.il/units/pharmacy/trufot/alonim/DOCETAXEL_TEVA_spc_worsening_May.15_1432629327960.doc עלון לרופא]}}} | ||
|עלון לצרכן={{{עלון לצרכן|}}} | |עלון לצרכן={{{עלון לצרכן|}}} | ||
|החמרות לעלון={{{החמרות לעלון|}}} | |החמרות לעלון={{{החמרות לעלון|}}} | ||
|מספר רישום={{{מספר רישום|146 31 33399 00}}} | |מספר רישום={{{מספר רישום|146 31 33399 00}}} | ||
| − | |תאריך עדכון=[[עדכון אחרון:: | + | |תאריך עדכון=[[עדכון אחרון::02/07/15]] |
|תמונת אריזה={{{תמונת אריזה|}}} | |תמונת אריזה={{{תמונת אריזה|}}} | ||
|שיווק הופסק={{{שיווק הופסק|לא}}} | |שיווק הופסק={{{שיווק הופסק|לא}}} | ||
גרסה מתאריך 02:10, 2 ביולי 2015
נתוני תרופה
במרשם 
| קבוצה פרמקולוגית (ATC4) | |
|---|---|
| מרכיב פעיל (ATC5) | Docetaxel 27.73MG / 1 ML L01CD02 |
| צורת מתן | I.V |
| צורת מינון | CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION |
| התוויה | Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
|
| תבנית:נתוני סל/תרופה/דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון - Docetaxel teva 20 mg/vial and 80 mg/vial | |
| עלון לרופא והחמרות לעלון | |
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון ® במאגר משרד הבריאות |
| חיפוש מאמרים | - |
|---|---|
| מידע ברשת | - |
| שם יצרן | PHARMACHEMIE B.V., THE NETHERLANDS |
| שם בעל הרישום | ABIC MARKETING LTD |
| רישיון | תאריך הגשה: 01/2011. רישיון מתאריך: 06/2011 |
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
- דף התרופה: vial
- לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את:
{{תרופה/vial}}
ב:
{{תרופה/vial
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
